Kristin Clement, Ph.D.
About Kristin Clement, Ph.D.
Kristin Clement, Ph.D., serves as the Chief Executive Officer at Bio-Val Consulting, LLC and is the Director of Analytical Development at Roivant Sciences. With extensive experience in assay development for infectious diseases and chronic conditions, she has contributed to significant projects, including those for Operation Warp Speed.
Work at Roivant Sciences
Kristin Clement, Ph.D. serves as the Director of Analytical Development, CMC Biologics at Roivant Sciences. She has held this position since 2024, working remotely from Charlotte, North Carolina. In her role, she focuses on the analytical development of biologics, contributing to the company's efforts in advancing therapeutic solutions.
Current Role at Bio-Val Consulting, LLC
Since 2013, Kristin Clement has been the Chief Executive Officer of Bio-Val Consulting, LLC, located in Cornelius, North Carolina. In this capacity, she oversees consulting services related to analytical development and regulatory compliance in the biopharmaceutical industry.
Previous Experience at Aruvant
Prior to her current roles, Kristin Clement worked as the Director of Analytical Development at Aruvant from 2019 to 2022. During her tenure, she was involved in the development of analytical methods for biologics, enhancing the company's capabilities in the field.
Educational Background
Kristin Clement earned her Bachelor of Arts in Pre-Medicine/Pre-Medical Studies from Capital University, where she studied from 1993 to 1997. She then pursued a Doctor of Philosophy in Cell/Cellular and Molecular Biology at the University of Cincinnati College of Medicine, completing her studies from 1997 to 2002.
Research and Development Expertise
Kristin Clement has extensive experience in developing clinical testing assays for various infectious diseases, including Ebola, Marburg, and Plague. She has also contributed to the development and validation of antibody detection assays for Operation Warp Speed, specifically targeting SARS-CoV2. Her work includes developing assays for chronic diseases and point-of-care tests for nerve agent exposure.